Pasien hipertensi seringkali mendapatkan beragam terapi atau polifarmasi untuk mencegah terjadinya komplikasi, namun berpotensi meningkatkan Drug Related Problems (DRPs). DRPs merupakan permasalahan yang mungkin terjadi ketika memperoleh terapi obat sehingga perlu dilakukan identifikasi. Tujuan penelitian ini adalah untuk mengetahui profil kejadian DRPs pada pasien hipertensi di Instalasi Rawat Jalan Rumah Sakit Pemerintah di Kota Mataram tahun 2018. Jenis penelitian ini adalah observasional dengan rancangan cross-sectional menggunakan data restrospektif dimana pengambilan sampel dilakukan secara purposive sampling. Permasalahan dan penyebab DRPs pada masing-masing pasien diklasifikasikan berdasarkan Pharmaceutical Care Network Europe Foundation Versi 8.03 (PCNE V8.03). Hasil penelitian ini diperoleh 113 pasien yang memenuhi kriteria inklusi dengan 75 pasien mengalami kejadian DRPs. Pola penggunaan antihipertensi di Instalasi Rawat Jalan RSUD Provinsi NTB tahun 2018 didominasi golongan Calcium Chanel Blocker (CCB) (47.42%). DRPs yang terjadi secara berurutan dari yang paling tinggi adalah kejadian efek buruk obat mungkin terjadi (50.44%), obat tidak tepat menurut pedoman/formularium (34.51%), obat tanpa indikasi (7.96%), gejala atau indikasi tidak diterapi (3.53%), dan terlalu banyak obat yang diresepkan untuk indikasi (3.53%).
Neuropathic pain which is suffered by stroke patients is a pain that occurred because of the damage of the somato sensory system. The first-line therapy of neuropathic pain can be done by using amitriptyline and gabapentin. Both amitriptyline and gabapentin have significant cost-effectiveness differences. This research aims to investigate the cost effectiveness of both amitriptyline and gabapentin through stroke patients who suffered neuropathic pain. The techniques of data collection applied to a total sampling which are 17 samples were collected. The data were retrospective by the year of 2017, meanwhile, the research was conducted from April to July 2019. Clinical evaluation of neuropathic pain is conducted by applying the Wong Baker Pain Rating Scale. Amitriptyline and gabapentin cost effectiveness analysis showed Average Cost-Effectiveness Ratio (ACER) are Rp 45.443,08 and Rp 52.241,52 and Incremental Cost-Effectiveness Ratio (ICER) Rp 72.636,87. Based on the results, Incremental Net Benefit (INB) showed that gabapentin is the most cost-effective than amitrityline with Rp + 59.078,37 score. Keywords: Stroke, neuropathic pain, amitriptyline, gabapentin, cost-effectiveness analysis
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.